FIELD: pharmaceutical industry.
SUBSTANCE: invention relates to the pharmaceutical industry, in particular to the use of a population of encapsulated pancreatic endocrine progenitor cells in the manufacture of a drug to reduce the blood glucose level in a patient, where pancreatic endocrine progenitor cells differentiate in vitro from cells, expressing markers characteristic of the pancreatic endoderm lineage in a medium with the addition of a factor capable of inhibiting BMP, and the TGF-beta receptor I kinase inhibitor, and where pancreatic endocrine progenitor cells express NGN3, NKX6.1, NeuroD, ISL1, PDX1, PAX4, NKX2.2, PAX6 or ARX.
EFFECT: above solution allows the use of a population of encapsulated pancreatic endocrine progenitor cells in the manufacture of a drug to reduce the blood glucose level in a patient.
9 cl, 3 dwg, 1 ex
